peptide,Qualitative Measure,Measurement Inequality,Quantitative measurement,Units,Allele Name,MHC allele class,Ref Type,Ref Date,Ref Title,Assay Method,Assay Group,Host Name,Description_Length,Normalized_QM,netmhcpan_ba_BAV,ann_BAV,smmpmbec_BAV,smm_BAV,mhcflurry_BAV,netmhcpan_ba_BAV_Normalized,ann_BAV_Normalized,smmpmbec_BAV_Normalized,smm_BAV_Normalized,mhcflurry_BAV_Normalized,VTAPERNet_BAV_Normalized,VTAPERNet_BAV
CIVYLSLSR,Positive-Intermediate,,39860.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.0209477204325033,1698.01,1331.99,1804.5129371190408,1555.2492479174653,2004.61,0.3126280353774539,0.3350668419952037,0.307005578457585,0.3207447595846033,0.2972864501244154,0.31218162178993225,1706.231390446194
ILRGSVAHK,Positive-High,,9460.0,nM,HLA-A*03:01,I,Literature,2023,Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.,cellular MHC/direct/fluorescence,half maximal effective concentration (EC50),Homo sapiens (human),9,0.1538802902055126,28.41,19.94,58.39289402991755,64.09143566447763,36.15,0.6906830151327352,0.7234021173201142,0.6240963448649228,0.6154902035269946,0.6684149291881433,0.4324817359447479,464.2493450358295
TVLEFILQK,Positive,,19.0,nM,HLA-A*03:01,I,Literature,2024,"Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine.",purified MHC/competitive/radioactivity,dissociation constant KD (~IC50),Homo sapiens (human),9,0.7278651279380701,64.28,63.2,92.54650023611966,82.56576326213263,31.39,0.615218682727728,0.6167847258823196,0.581533825884072,0.5920808180875268,0.6814639560757221,0.36289867758750916,985.6438211724641
